STOCK TITAN

Tenaya Therapeutics, Inc. - TNYA STOCK NEWS

Welcome to our dedicated news page for Tenaya Therapeutics (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tenaya Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tenaya Therapeutics 's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.51%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.51%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.4%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
Tenaya Therapeutics, Inc.

Nasdaq:TNYA

TNYA Rankings

TNYA Stock Data

356.47M
42.73M
1.53%
77.18%
3.93%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SOUTH SAN FRANCISCO

About TNYA

tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.